Skip to main content
. 2016 Oct 13;78(5):1041–1049. doi: 10.1007/s00280-016-3163-y

Table 7.

Second primary malignancies (SPMs)

SPM n (%) Time to enrollment (months) sVRD (courses) Prior therapies
Acute lymphoblastic leukemia 1 (6.3) 38 18 VAD, ASCT
Myelodysplastic syndrome 1 (6.3) 60 7 VAD, Bd

VAD vincristine, adriamycin and dexamethasone, ASCT autologous hematopoietic stem cell transplantation, Bd bortezomib plus dexamethasone